Theravance Biopharma, Inc.
TBPH
$18.43
-$1.18-6.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.99M | 26.20M | 15.39M | 18.75M | 16.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.99M | 26.20M | 15.39M | 18.75M | 16.87M |
| Cost of Revenue | 8.11M | 10.49M | 11.45M | 9.45M | 9.27M |
| Gross Profit | 11.88M | 15.71M | 3.94M | 9.30M | 7.60M |
| SG&A Expenses | 18.33M | 18.43M | 18.37M | 18.50M | 16.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.45M | 28.92M | 29.82M | 27.95M | 26.14M |
| Operating Income | -6.46M | -2.73M | -14.43M | -9.20M | -9.28M |
| Income Before Tax | -2.89M | 73.21M | -14.14M | -8.94M | -10.05M |
| Income Tax Expenses | -6.50M | 18.37M | -559.00K | 6.59M | 2.65M |
| Earnings from Continuing Operations | 3.62M | 54.84M | -13.58M | -15.53M | -12.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.62M | 54.84M | -13.58M | -15.53M | -12.70M |
| EBIT | -6.46M | -2.73M | -14.43M | -9.20M | -9.28M |
| EBITDA | -6.05M | -2.32M | -14.02M | -8.78M | -8.85M |
| EPS Basic | 0.07 | 1.09 | -0.27 | -0.31 | -0.26 |
| Normalized Basic EPS | -0.04 | 0.91 | -0.18 | -0.11 | -0.11 |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 | -0.26 |
| Normalized Diluted EPS | -0.03 | 0.90 | -0.18 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 50.52M | 50.18M | 49.71M | 49.31M | 49.04M |
| Average Diluted Shares Outstanding | 51.91M | 50.73M | 49.71M | 49.31M | 49.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |